坎地沙坦酯对高血压脑梗死患者C-反应蛋白水平影响研究

目的：研究坎地沙坦酯对高血压脑梗死患者C-反应蛋白（C reactive protein,CRP）水平的影响。方法：选取高血压脑梗死患者160例,随机分为常规治疗组和坎地沙坦酯治疗组。常规治疗组（n=80）采用急性脑梗死常规治疗,如病情稳定后血压仍控制不理想,加用血管紧张素Ⅱ受体拮抗剂以外的降压药物,坎地沙坦酯治疗组（n=80）在常规治疗基础上病情稳定后血压仍明显偏高,给予坎地沙坦酯4～8mg口服,1次/d,8周为1个疗程,观察入院时、坎地沙坦酯治疗1、8周后CRP水平的变化。结果：脑梗死组患者CRP水平明显高于正常对照组（P〈0.01）,常规治疗组和坎地沙坦酯治疗组治疗1周后,上述指标与治疗前相比均有下降（P〈0.05）,治疗8周后坎地沙坦酯组改变更加显著（P〈0.01）,两组血压均控制稳定。结论：用坎地沙坦酯治疗后,高血压脑梗死患者C-反应蛋白水平明显降低,血压控制稳定,坎地沙坦酯能够调控血压,同时可降低脑梗死患者C-反应蛋白水平,预防脑梗死复发,从而减少高血压脑梗死的不良预后。

Study on the effects of Candesartan Cilexetil on high blood pressure cerebral infarct patient's C reactive protein level

Objective：To study the effect of Candesartan Cilexetil on the C reactive protein（CRP） level of high blood pressure cerebral infarct patients. Methods：160 cases of high blood pressure cerebral infarct patients were treated randomly with routine therapy（n=80） and Candesartan Cilexetil（n=80） . Routine group was treated with conventional therapy of acute cerebral infarction and taking antihypertensive drug rather than angiotensin Ⅱ receptor antagonist if illness was stable but blood pressure remained unsatisfactory. Candesartan Cilexetil group was treated with oral Candesartan Cilexetil 48 mg once a day,and 8 weeks was a treatment course after conventional therapy. The CRP level changes of admission 1 week therapy and 8 weeks therapy was observed. Results：CRP levels of cerebral infarction group were significantly higher than the control group（P〈0.01） ,CRP of routine treatment group and the Candesartan Cilexetil treatment group decreased significantly（P〈0.05） after 1 week,Candesartan Cilexetil group changed more significant than routine group（P〈0.01） ,and blood pressure kept stable. Conclusion：After Candesartan Cilexetil therapy the cerebral infarction patients＇ C reactive protein decreases significantly and blood pressure keeps stable. Candesartan Cilexetil can control blood pressure but also reduce the CRP level and prevent cerebral infarction recurrence and thereby reduces high blood pressure cerebral infarct adverse prognosis.